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The  hypercalcemia  of sarcoidosis  is  thought  to  result  from  the  extrarenal 
overproduction  of an  active  vitamin  D  sterol  (1,  2).  We reported  (3,  4)  that 
cultured pulmonary alveolar macrophages (PAM) ~ from patients with sarcoidosis 
are  capable of metabolizing  25-hydroxyvitamin  D~ (25-OH-Ds) to  la,25-dihy- 
droxyvitamin  D~ [1,25-(OH)2-Ds], suggesting that  1,25-(OH)2-D3, the naturally 
occurring active metabolite of vitamin  D3, is a  hypercalcemia-causing factor in 
sarcoidosis. However, the characteristics of this 25-OH-Ds-converting activity of 
sarcoid  PAM  in  vitro  are  poorly  understood.  It  does  appear  that  the  l a- 
hydroxylation process is specific for cells derived from patients with sarcoidosis: 
1,25-(OH)2-D~  is  not  synthesized  by  PAM  from  patients  with  other  types  of 
pulmonary disease (4).  In addition, the specific activity of the cellular converting 
reaction  is  greatest  in  PAM  derived  from  patients  with  diffuse,  infiltrative 
pulmonary disease and clinical evidence of abnormal calcium metabolism (3, 4). 
The  aim  of the  current  report  is  to  describe  the  kinetics  of  1,25-(OH)2-D3 
production by these cells in vitro and to delineate factors that may be important 
regulators of the conversion reaction. 
Materials and Methods 
Vitamin D3 Sterols.  ['SH-la,2a]vitamin  D3 (sp act, 25 Ci/mmol);  [SH-26,27-methyl]25- 
hydroxyvitamin Ds ([SH]25-OH-Ds)(161  Ci/mmol);  and [~H-26,27-methyl]24(R),25-di- 
hydroxyvitamin Ds ([3H]24,25-(OH)~-D~) (158 Ci/mmol) were obtained from Amersham 
Corp., Arlington  Heights, IL.  Authentic 25-OH-Ds was a gift from Dr. John Babcock 
(Upjohn Co., Kalamazoo,  MI). Authentic, crystalline standards of 1,25-(OH)2-D~, 24,25- 
(OH)2-Ds, la-hydroxyvitamin Ds (Ia-OH-D~),  25,26-dihydroxyvitamin  D~ [25,26-(OH)2- 
D3]), and 1,24(R),25-trihydroxyvitamin  D~ [ 1,24,25-(OH)3-D~] were generously provided 
by Dr. Milan Uskokovic (Hoffmann-La Roche, Inc., Nutley, NJ). All labeled and unlabeled 
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TABLE  1 
Clinical  Data on Patients With Sarcoidosis 
Urinary cal-  Serum angi- 
cium excre-  Serum  1,25-  otensin-con-  Patient  Age  Sex  Serum calcium  tion 
(mg Ca/100  (OH)2-D  verting en- 
ml GF)*  zyme activity 
yrs  mg/dl  pg/ml  lUll 
1  55  F  14.4  1.34  76  59 
2  33  F  10.0  0.31  59  81 
3  25  F  9.6  0.11  40  31 
4  26  E  12.2  ***--*  63  59 
5  31  M  14.5  0.92  68  92 
Nt)rmal range:  8.5-10.5  <0.16  30-65  10-35 
* GF, glomerular filtrate. 
* Obtained during furosemide  therapy. 
sterols were purified on silica Sep-Pak cartridges (Waters Associates, Milford, MA) before 
use.  Dexamethasone sodium phosphate was obtained from Merck Sharp & Dohme Div., 
Merck & Co., Inc., West Point, PA. Preparations of human immune (gamma) interferon 
(1FN-'y) and human alpha interferon  (IFN-a) were purchased from Interferon Sciences, 
New Brunswick, NJ. 
Macrophage Cultures.  Primary monolayer cultures of PAM were established by stand- 
ard technique (5) from the alveolar lavage fluid of five patients with diffuse pulmonary 
sarcoidosis (biopsy proven). Clinical laboratory data on patients at the time of lavage are 
shown in Table I. The cells were plated and maintained  in RPMI  1640 medium (Gibco 
Laboratories,  Grand  Island,  NY)  supplemented  with  10%  fetal  calf serum  (FCS)  (KC 
Biological, Inc., Lenexa, KA), 10 ug/ml insulin, 4 nM glutamine, 50 U/ml penicillin, and 
50 mg/ml streptomycin at 37°C in an atmosphere of 95% air/5% CO2. The medium was 
replaced with fresh medium every 3rd d. After 3 d in culture, >98% of the adherent cell 
population was esterase positive (6). 
Metabolism Experiments.  After 5 d in primary culture, the capacity of confluent PAM 
monolayers from each patient  to metabolize 5 nM  [3H]25-OH-D3 to [3H]l,25-(OH)2-D3 
was established.  Thereafter,  metabolism experiments were performed in cultures (0.25- 
1.0 X  106 cells/well) ranging in age from 7 to  17 d, by previously described techniques 
(3).  Briefly, cultures were preincubated  for 16 h in serum-free medium with or without 
vitamin D3 sterols (solubilized  in 0.2%  ethanol),  dexamethasone,  or IFN. This medium 
was replaced with BGJB medium (Gibco Laboratories) containing radiolabeled sterol and 
incubated  for  3  h  in  the  incubator:  accumulation  of generated  [3H]l,25-(OH)-D3 was 
linear over 5  h  (Fig.  1).  All subsequent  experiments  were incubated for 3 h.  A  known 
amount  (150  ng)  of unlabeled  sterol  was  then  added  to  the  incubation  medium,  the 
medium was collected, the monolayer was harvested  by scraping, and the medium  and 
cells were extracted in methanol/methylene chloride. The lipid extracts were chromato- 
graphed on Sep-Pak cartridges (7) to obtain the vitamin D metabolite fraction of interest. 
This fraction was then subjected to a three-step purification procedure on normal-phase 
high  performance  liquid  chromatography (HPLC)  over  a  3.9  mm  X  30  cm  #-Porasil 
column (DuPont Instruments,  Wilmington,  DE). The first chromatographic purification 
was performed in n-hexane/methanol/isopropanol  (92:4:4) followed by HPLC in meth- 
ylene chloride/methanol (98:2) and methylene chloride/isopropanol (94:6). The fractions 
containing the  authentic  standard  of interest  were  retained,  pooled,  and  subjected  to 
scintillation counting to determine the yield of metabolite. ADAMS  AND  GACAD  757 
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FICURE  1.  Synthesis of [~H]I,25-(OH)2-Ds from 5 nM [SH]25-OH-D~ by cultured PAM from 
a patient with sarcoidosis over time. Each point is the mean of duplicate determinations. 
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FIC;URE 2.  Kinetic analysis of [SH]l,25-(OH)~-Ds  synthesis from [SH]25-OH-D3 by cultured 
human PAM from a representative patient (patient 1, Table I1) with sarcoidosis.  Established 
monolayer cultures of PAM containing 1.5 ×  10 ~ cells per culture were exposed to increasing 
concentrations of [SH]25-OH-Ds for 3 h. A single-reciprocal plot of the data (insert) yielded a 
K,, (x intercept) and velocity (V,,ax, 1/y intercept) of 53  nM and 6.3  fmol. 10  -6 cells.rain  -l, 
respectively. Each point is the mean of duplicate determinations. 
Results 
Fig. 2  depicts the synthesis of [3H]l,25-(OH)2-D3  by PAM monolayer cultures 
derived  from  a  representative  patient  with  sarcoidosis and  abnormal  calcium 
metabolism, during  incubation  with  increasing amounts  of [3H]25-OH-D3.  The 758  VITAMIN  D  METABOLISM  BY  MACROPHAGES  lN  SARCOIDOSIS 
TABLE  I1 
Kinetic Analysis of [SH] I,25-(OH)~-D3 Synthesis by Cultured PAM 
from Patients With Sarcoidosis 
Vmax 
Patient  Substrate Range  (fmol. 10  -6 cells.  Km 
min  -l) 
nM  nM 
1  3-150  5.9  52 
1-500  6.3  53 
2  3-180  11.0  70 
3  5-320  1.2  76 
4  10-300  9.1  109 
5  10-300  40.6  210 
rate  of ['~H]l,25-(OH)2-D3  synthesis  was  dependent  on  the  concentration  of 
substrate,  [3H]25-OH-D3 (Fig.  2).  A single-reciprocal plot of these data (insert, 
Fig. 2) demonstrated the Km for [3H]25-OH-D3 (concentration resulting in half- 
maximal formation rate of [~H]l,25-(OH)2-Ds) to  be  53  nM.  The cumulative 
kinetic data for PAM derived from all five patients with sarcoidosis is summarized 
in Table  II. Cells from all patients produced a  labeled metabolite that cochro- 
matographed with authentic 1,25-(OH)2-D~.  The yield of metabolite was greater 
in  PAM cultures derived from the four patients with a  clinical abnormality in 
calcium homeostasis; it resulted primarily from an increase in the velocity (Vma~) 
of the  conversion  reaction.  The  Km  for  [3H]25-OH-D3  varied  only  fourfold 
between PAM from five different patients, whereas the V  .... varied nearly 40- 
fold. Two examinations, 5 d apart, of the kinetics of [~H] 1,25-(OH)2-D3  produc- 
tion by PAM from the same host (patient 1, Table II) yielded comparable results. 
Interestingly, no  radiolabeled  product  with  the  chromatographic mobility of 
24,25-(OH)2-D~  was  observed even  in  cell  extracts  from  cultures exposed  to 
concentrations of substrate [SH]25-OH-Ds as high as 500 nM. 
A study of the substrate specificity of the PAM lot-hydroxylation reaction was 
made in cultures from patient 2 using [~H]25-OH-D3, [3H]24,25-(OH)2-D3, and 
[:~H]vitamin  D3 as substrates (Fig.  3).  The presence of an additional  hydroxyl 
function at C24 in the side chain did not hinder hydroxylation at C1  in the A 
ring of the molecule. The yield of [3H]l,24,25-(OH)3-D3 from [~H]24,25-(OH)2- 
D:~ was not significantly different from the amount of [3H]l,25-(OH)~-D3 made 
from  [3H]25-OH-D~.  However,  absence  of the  C25  hydroxyl  group  had  a 
profound inhibitory effect on the generation of l~-hydroxylated product. The 
specific activity of the PAM conversion reaction of [3H]vitamin D3 to  [3H]I~- 
OH-Ds was only ! 5% of that observed with the side chain-substituted substrates. 
In  an  attempt  to  discern  factors that  influence  1,25-(OH)2-D~  synthesis by 
sarcoid macrophages in vivo, we investigated in vitro the effects of preexposure 
of PAM to  1,25-(OH)2-D3  or to glucocorticoid, dexamethasone, or human IFN, 
known stimulators of macrophage activity. Fig. 4  shows the effects of preincu- 
bation of PAM monolayers from patient 5 with increasing amounts of radioinert 
1,25-(OH)z-Ds on the synthesis of [3H] 1,25-(OH)2-D~.  Exposure to 0.75 and 7.5 
nM  1,25-(OH)2-D3  had little effect on [SH]l,25-(OH)z-D~ production.  Preincu- ADAMS  AND  GACAD  759 
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FIGURE 3.  la-Hydroxylated metabolite formation by cultured, human  PAM from a patient 
with sarcoidosis and altered calcium metabolism (patient 2, Table II) after incubation with 5 
nM  [~H]25-OH-D3,  [SH]24,25-(OH)s-Ds,  and  [SH]vitamin  D3.  The yield of metabotite was 
determined by the amount of radiolabeled product that cochromatographed with authentic 
1,25-(OH)2-Ds,  1,24,25-(OH)s-Ds, and  la-OH-Dn, respectively. Each value is the mean +  SD 
of triplicate determinations. 
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FIGURE 4.  Effects  of preincubation  with  radioinert  1,25-(OH)~-Ds  on  [SH]l,25-(OH)2-D~ 
synthesis  in  cultured  human  PAM  from  a  hypercalcemic host  (patient  5  in  Table  I)  with 
sarcoidosis. PAM were preincubated  for  18 h in culture medium containing 0.5%  FCS with 
or without radioinert 1,25-(OH)2-D~.  For determination of [SH] t,25-(OH)2-Ds from 5 nM [SH] 
25-OH-Ds, the medium was removed and replaced with serum-free BGJB  medium. Each value 
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FIGURE 5.  Effect  of dexamethasone on [SH]l,25-(OH)2-D3 synthesis by cultured, human 
PAM from two patients (patients 1 [A] and 4 [I]; see Table I) with sarcoidosis.  PAM monolayers 
were preincubated for  18 h in serum-free medium with or without dexamethasone. The 
medium was removed and replaced with serum-free BGJB medium for determination of [SH] 
] ,25-(OH)2-D3 synthesis  from 5 nM [SH]25-OH-D3. Each point is the mean of triplicate [A] or 
duplicate [O] determinations. 
bation with 75 nM  1,25-(OH)~-D3  reduced [3H] 1,25-(OH)2-D~ synthesis by only 
20%,  indicating  a  relative  resistance  to  product  inhibition  of the  conversion 
reaction. Preincubation of cells from two subjects (patients 1 and 4) with sarcoid- 
osis and hypercalcemia with increasing amounts of dexamethasone resulted in a 
dose-dependent inhibition of [~H] 1,25-(OH)2-D~ synthesis (Fig. 5). Although the 
half-maximal inhibitory concentration of dexamethasone was the same in cells 
from  both  individuals  (0.2  nM),  the  magnitude  of the  decrease  in  hormone 
production  was  much  greater  in  cells  from  patient  1.  By comparison,  IFN--y 
stimulated [~H]l,25-(OH)2-D~  synthesis by  sarcoid  PAM.  As  shown  in  Fig.  6, 
preincubation of PAM from three different patients with IFN-'y exerted a dose- 
dependent stimulatory effect on the conversion of 5 nM [3H]25-OH-D3  to [3H] 
1,25-(OH)2-Ds, in each case. At the lower concentrations of IFN the stimulatory 
action  was specific for  IFN-7.  Preincubation  of cells  with  1,000  #g/ml  IFN-c~ 
resulted in only a modest increase (50%) in [3H] 1,25-(OH)2-D~ synthesis in PAM 
from the host whose cells had the greatest increase (200%) in hormone produc- 
tion  after exposure  to  IFN-'y.  In  cells  from  a  second  host,  IFNoa exerted  an 
inhibitory effect on the PAM [3H]25-OH-D3  conversion reaction at all concen- 
trations of the lymphokine. A kinetic analysis of the IFN-7-mediated stimulatory 
action is depicted in Fig. 7. IFN-3' clearly increased the yield of [3H] 1,25-(OH)2- 
D:~ at each  concentration  of substrate  ['~H]25-OH-D~.  As  demonstrated in  the ADAMS  AND  GACAD  761 
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FIGURE 6.  Effect of IFN-~, (closed symbols) and  IFN-a (open symbols) on [SH]l,25-(OH)~- 
Ds synthesis by cultured,  human  PAM from three patients (patients  3  [[--I], 4  [A],  5 [Q]; see 
Table I) with sarcoidosis. Cell monolayers were preincubated for 18 h in medium containing 
1.0% FCS with or without increasing amounts of IFN-~, or IFN-c~. The medium was removed 
and replaced with serum-free BGJB medium  for determination of [SH]l,25-OH-Ds synthesis 
from 5 nM [SH]25-OH-Ds. Each point is the mean of duplicate determinations. 
reciprocal plot of the data (insert,  Fig.  7),  the majority of the increase in  [~H] 
1,25-(OH)z-Da synthesis was attributable  to an  increase in  the velocity of the 
conversion reaction.  The  Vm,x of la-hydroxylation was  34.5  fmol. 10 -6  cells. 
rain -1 after preincubation of cells with IFN-~,, and 9.1  fmol. 10 -6 celis.min  -1 in 
its absence. The K,1, for [aH]25-OH-Da with or without IFN-7 were similar,  109 
and 145 nM, respectively. 
Discussion 
The conversion of 25-OH-D to 1,25-(OH)2-D in nonpregnant, mammalian and 
avian species is a  strictly controlled metabolic event catalyzed by a cytochrome 
P-450  mixed-function oxidase located in  the mitochondria of renal epithelial 
cells (8). The only pathologic human condition in which there is good evidence 
for the extrarenal synthesis of 1,25-(OH)2-D is sarcoidosis (9). Previous data from 
our laboratory (3) suggest that the macrophage, a ubiquitous constituent of the 
noncaseating granulomata of sarcoidosis, is the synthetic source of 1,25-(OH)2- 
D  in  the disease.  In  the current report,  kinetic analysis of the  25-OH-Da-lct- 
hydroxylation reaction in cultured PAM from patients with sarcoidosis yielded 
an apparent Km for 25-OH-Da of 52-210 nM. This value is in the range previously 
reported for the 25-OH-D3-24-hydroxylase in cultured mouse kidney cells (10), 
dispersed rat  renal epithelial  cells (11),  mouse kidney homogenates (12),  and 
reconstituted mammalian enzyme (13).  If the proposed affinities of the renal 
enzyme and the PAM hydroxylating mechanism in vitro are applicable in vivo, 
then one might predict that the sarcoid macrophage competes with the renal 1ot- 
hydroxylase for its preferred substrate, 25-OH-D3. 
Although the PAM  l a-hydroxylation reaction and the renal  l a-hydroxylase 
are similar in their affinity and specificity for 25-hydroxylated substrates, there 762  VITAMIN  D  METABOLISM  BY  MACROPHAGES  IN  SARCOIDOSIS 
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FIGURE  7.  Kinetic analysis of [SH]l,25-(OH)2-Ds synthesis by cultured, human PAM from a 
single hypercalcemic patient with sarcoidosis (patient 4, Table If) preincubated in the presence 
(O)  or  absence  (0)  of  IFN-7.  PAM  monolayers  were  preincubated  for  18  h  in  medium 
containing  1.0%  FCS  with  or  without  1,000  U/1  1FN-7.  This medium  was  removed  and 
replaced with serum-free BGJ~ medium for determination of [Sill 1,25-(OH)2-Ds synthesis in 
the presence of increasing amounts of [SH]25-OH-D3.  Each point is  the mean of duplicate 
determinations. A  single-reciprocal plot of the data (insert) disclosed a  Km for 25-OH-D3 (x 
intercept) and velocity (V  ....  1/y intercept) of  109  nM  [SH]25-OH-Ds  and  34.5  fmol. 10  -6 
cells, min  -l, respectively, in cells exposed to IFN-~, and 145 nM [SH]25-OH-Ds and 9.1 fmol. 
10  -6 cells, min  -~ in cells not exposed to IFN-7. 
appear to  be some important differences between the two.  First,  even in  the 
presence of high concentrations of substrate 25-OH-Ds or after preincubation 
with high concentrations of 1,25-(OH)2-Ds,  a  potent inducer of the renal 25- 
OH-D3 24-hydroxylase (14), the PAM  1  a-hydroxylation process was not accom- 
panied by detectable 24-hydroxylating activity. An accompanying 24-hydroxylase 
is  a  characteristic of all  the  other  renal  lc~-hydroxylation systems previously 
described (10-13,  15,  16). Therefore, unlike the situation in the renal epithelial 
cell,  the  sarcoid  macrophage  does  not  have a  24-hydroxylase competing for 
substrate.  Furthermore,  1,25-(OH)2-D~  synthesized in  the sarcoid PAM  is not 
likely to be metabolized to  1,24,25-(OH)3-Ds,  a  metabolite that is biologically 
less potent than  1,25-(OH)2-D3  (17,  18).  A  second discrepancy is the apparent 
lack of metabolic control in the 1  a-hydroxylation of 25-OH-D in hypercalcemic 
patients  with  sarcoidosis.  Patients  1 and  5  reported  here (Table  I) are  good 
examples of this event in vivo. Despite being hypercalcemic, their serum level of 
1,25-(OH)2-D was in the supranormal range, constituting inappropriate genera- ADAMS AND GACAD  763 
tion of hormone. This clinical observation was born out in vitro. Preincubation 
of cultured  PAM  from a  hypercalcemic host with  1,25-(OH)2-Ds  reduced the 
yield of [3H]l,25-(OH)-D3;  however, the degree of suppression [only 20%  with 
75 nm 1,25-(OH)2-D~] was far less than that previously reported for the suppres- 
sion of the  25-OH-D~-la-hydroxylase  either in preparations of renal  tissue in 
vitro after pretreatment of vitamin D-deficient animals in vivo with 1,25-(OH)2- 
D3 (19)  or in cultured kidney cells preincubated in medium containing  10 -s- 
10 -7 M  1,25-(OH)~-D3 (10,  15). These data indicate that the inhibitory effect of 
1,25-(OH)2-D~ on its own synthesis or, as proposed by Eisman et al. (20),  1,25- 
(OH)2-Ds  induction of its own metabolism, may not be  fully operative  in  the 
PAM  l a-hydroxylation  reaction.  The lack  of accompanying 24-hydroxylating 
activity and significant product inhibition of the PAM 25-OH-Ds-la-hydroxyla- 
tion reaction, coupled with the relatively high affinity of the macrophage con- 
version reaction  for  25-OH-D~,  suggests that the sarcoid macrophage has the 
potential to rival the naturally occurring renal enzyme in its efficiency of 1,25- 
(OH)2-D~  synthesis. 
These dissimilar characteristics of the PAM and renal hydroxylating mecha- 
nisms  suggest  that  the  sarcoid  macrophage  does  not  harbor  the  classic  l~- 
hydroxylase (21).  Moreover,  it is also  unlikely that  1,25-(OH)2-D~  synthesis in 
sarcoid PAM occurs via the mitochondrial cytochrome P-450-catalyzed peroxy- 
genase pathway recently reported by Warner (21). In this NADPH-independent 
system, both  1,25-(OH)2-D~  and  24,25-(OH)2-D3  are generated from substrate 
25-OH-D3.  No  24,25-(OH)2-D3  production  was  identified  in  our  metabolism 
experiments, even at high concentrations of 25-OH-Ds.  It is possible that  the 
PAM  la-hydroxylation reaction is linked to the production of reactive oxygen 
intermediates. The generation of hydrogen peroxide by activated human mon- 
ocytes is exquisitely sensitive to glucocorticoids (23) and may explain the steroid- 
mediated inhibition of 1,25-(OH)2-D3  synthesis by sarcoid PAM.  Interestingly, 
the suppressive action in vitro correlates with the long-recognized antihypercal- 
cemic action of glucocorticoids in vivo in patients with sarcoidosis (24). 
In light of the suppressive actions of glucocorticoids on the generation of 1,25- 
(OH)2-D3  by  sarcoid  PAM,  we  were  curious  to  know  whether  IFNs,  known 
stimulators of macrophage action, might enhance sterol synthesis by these cells. 
Mononuclear inflammatory cells, derived from the alveolar space of patients with 
sarcoidosis and high intensity alveolitis, are prolific in their synthesis of lympho- 
kines, including interleukin  1, interleukin 2, and IFN-3, (25).  As demonstrated 
in  Figs.  6  and  7,  IFN-3~ accelerates  the velocity of the conversion reaction  in 
PAM  in  vitro,  increasing the synthetic  yield of  1,25-(OH)2-Ds  by as  much as 
200%.  Whether  IFN-3'  is an important modulator of macrophage  1,25-(OH)2- 
D3 synthesis in  vivo, and whether  1,25-(OH)2-D3,  recently shown (26)  to be a 
specific and potent inhibitor of human T  helper/inducer lymphocyte function, 
is  a  biologically  active  lymphokine  in  the  alveolar  space  in  sarcoidosis,  are 
intriguing but yet unanswered questions. 
Summary 
We investigated the  l a-hydroxylation of vitamin Ds sterols by cultured pul- 
monary  alveolar  macrophages  (PAM)  from  patients  with  sarcoidosis  with  or 764  VITAMIN  D  METABOLISM BY  MACROPHAGES IN  SARCOIDOSIS 
without  clinically abnormal  calcium  homeostasis.  Like the  naturally occurring 
renal  l~-hydroxylase,  the  PAM  lo~-hydroxylation  reaction  exhibited  a  high 
affinity for 25-hydroxyvitamin Ds  (25-OH-Ds)  and a  preference for substrates 
containing a  25-hydroxyl group in the side chain of the sterol. Unlike the renal 
enzyme,  the  PAM  l o~-hydroxylating mechanism  was  not  accompanied  by  24- 
hydroxylating activity, even after preincubation with  75 nM  1,25-dihydroxyvi- 
tamin  D3 [1,25-(OH)2-D3] or exposure to high concentrations of substrate (500 
nM 25-OH-D3). The PAM 25-OH-D3-1 a-hydroxylation reaction was stimulated 
by gamma interferon and inhibited by exposure to the glucocorticoid dexameth- 
asone. The characteristics of the PAM hydroxylation process in vitro appear to 
reflect the  efficiency of the  extrarenal  production  of  1,25-(OH)2-Ds  and  the 
therapeutic efficacy of glucocorticoids in patients with sarcoidosis and disordered 
calcium metabolism. 
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